Welcome to our dedicated page for Encision SEC filings (Ticker: ECIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Encision Inc. (ECIA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports and other documents filed with the U.S. Securities and Exchange Commission. Encision is a Boulder, Colorado-based medical device company that designs surgical instruments for minimally invasive procedures and owns patented Active Electrode Monitoring (AEM®) technology.
Through its filings, Encision reports details that go beyond headline financial results in press releases. Investors can review information on product and service revenue, gross margins, operating expenses, financing arrangements such as secured notes and lines of credit, and changes in shareholders’ equity. These documents help explain how Encision funds its operations, invests in research and development, and manages its capital structure over time.
Recent Form 8-K filings have disclosed corporate governance and leadership changes, including director resignations and the resignation of the company’s CEO and President, along with the appointment of an Interim President and CEO. Such filings provide context on board composition, management transitions, and the company’s stated reasons for key changes.
On Stock Titan, Encision’s filings are updated as they are made available through EDGAR, and AI-powered tools summarize the key points in plain language. Users can quickly identify items related to executive departures, board changes, financing events, and other material developments, then drill down into the full text for deeper analysis.
This page is a resource for anyone seeking to understand Encision’s regulatory history, including how management describes risks, capital needs, and strategic decisions in official filings, and how those disclosures relate to the company’s reported financial performance and technology focus.
Encision Inc. (ECIA) reported a weaker quarter for the three months ended September 30, 2025. Total revenue was $1.53 million, down from $1.76 million a year ago, as product sales fell 10% to $1.48 million and service revenue decreased to $46,248 following a brief project suspension by a customer. Gross margin was 46% versus 47% a year earlier. The company posted a net loss of $267,833, compared with a $170,262 loss last year.
Cash declined to $71,731 from $257,433 at March 31, 2025. Working capital was $1.38 million, and current borrowings under the line of credit were $31,706 with up to $968,294 available, subject to eligible receivables. Management states there is substantial doubt about continuing as a going concern without additional financing, though a private placement on August 19, 2025 added $500,000 and increased shares outstanding to 16,879,645.
The quarter also reflected lower sales and marketing and G&A costs, offset by higher R&D. Disclosure controls were deemed not effective due to inadequate segregation of duties.
Encision, Inc. disclosed a board change. Director Patrick Pace resigned on October 30, 2025. The company stated the resignation was not the result of any dispute or disagreement regarding its operations, policies, or practices.
The filing records the change under Item 5.02 and was signed by Controller and Principal Accounting Officer Brandon Shepard.